



Angiopoietin-like protein 3, an emerging cardiometabolic therapy target 
with systemic and cell-autonomous functions 
 
Hanna Ruhanen1,2, P.A. Nidhina Haridas1, Matti Jauhiainen1, and Vesa. M. Olkkonen1,3* 
 
1Minerva Foundation Institute for Medical Research, Helsinki, Finland 
2Molecular and Integrative Biosciences, University of Helsinki, Finland  
3Department of Anatomy, Faculty of Medicine, University of Helsinki, Finland 
 
*Corresponding author at: Minerva Foundation Institute for Medical Research, Biomedicum 


















Angiopoietin like protein 3 (ANGPTL3) is best known for its function as an inhibitor of 
lipoprotein and endothelial lipases. Due to the capacity of genetic or pharmacologic 
ANGPTL3 suppression to markedly reduce circulating lipoproteins, and the documented 
cardioprotection upon such suppression, ANGPTL3 has become an emerging therapy target 
for which both antibody and antisense oligonucleotide (ASO) therapeutics are being 
clinically tested. While the antibody is relatively selective for circulating ANGPTL3, the ASO 
also depletes the intra-hepatocellular protein, and there is emerging evidence for cell-
autonomous functions of ANGPTL3 in the liver. These include regulation of hepatocyte 
glucose and fatty acid uptake, insulin sensitivity, LDL/VLDL remnant uptake, VLDL 
assembly/secretion, polyunsaturated fatty acid (PUFA) and PUFA-derived lipid mediator 
content, and gene expression. In this review we elaborate on (i) why ANGPTL3 is 
considered one of the most promising new cardiometabolic therapy targets, and (ii) the 
present evidences for its intra-hepatocellular or cell-autonomous functions. 
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Angiopoietin like 3 (ANGPTL3) belongs to the angiopoietin-like protein family consisting of 
8 members structurally similar to angiopoietins [1]. ANGPTL3 was first identified by Conklin 
et al. [2]. It is mainly expressed in liver; very low expression is also detectable in kidney 
podocytes but its role in podocyte function is not fully understood. The protein consists of an 
N-terminal signal peptide, a coiled-coil region, a linker region, and a C-terminal fibrinogen-
like domain (FLD; Fig. 1). ANGPTL3 expression is regulated positively by liver X receptor 
(LXR) and negatively by insulin, leptin and thyroid hormone [3-6]. The main function of 
ANGPTL3 is in the regulation of lipid metabolism, where it acts synergistically with the 
related ANGPTL4 and ANGPTL8, forming a functionally essential protein-protein complex 
with the latter [7,8]. Unlike ANGPTL3, ANGPTL4 and ANGPTL8 are expressed in both 
adipose tissue and liver [6,9,10]. 
Angptl3 was in an early study found to associate with a hypolipidemia trait in a 
moderately obese mouse strain [11], and knock-out of Angptl3 was reported to result in a 
hypotriglyceridemia phenotype [12]. Later, genome-wide association study (GWAS) in 
human subjects revealed that markers in the region of ANGPTL3 are associated with 
circulating triglyceride (TG) levels [13]. Moreover, loss-of-function (LOF) variants of 
ANGPTL3 were found to associate with reduced plasma LDL- and HDL-cholesterol (LDL-C, 
HDL-C) and TG [14]; Several other studies soon replicated these observations [10,15,16]. 
The major known function of ANGPTL3 is to inhibit the activity of lipoprotein lipase (LPL), 
an enzyme that hydrolyses TG in TG-rich lipoproteins (TRL) [10,17]. Moreover, ANGPTL3 
also inhibits endothelial lipase (EL) [18], which provided a putative explanation for its effects 
on circulating HDL-C as shown in vivo in mouse [19]. However, ANGPTL3 deficient human 
subjects displayed similar EL activity as in control individuals, suggesting that other 
mechanisms may account for the reduction of HDL levels in these subjects [16]. Importantly, 
ANGPTL3 LOF variant carriers are protected from coronary artery disease [20]. Due to this 
cardioprotective effect, ANGPTL3 has emerged as a novel therapeutic target for 
cardiovascular diseases (CVD). ASO and monoclonal antibody-based therapeutics 
targeting ANGPTL3 are in clinical trials [21-25]. While the function of ANGPTL3 in regulating 
plasma lipoprotein levels is rather well studied and reviewed [1,26-29], very little is known 
about the putative intracellular functions of ANGPTL3. Since ANGPTL3-targeting ASO 
drugs, which inhibit the hepatocellular expression of the protein, are under clinical trial, it is 




address two crucial aspects of the protein: (i) Why is ANGPTL3 considered a promising 
therapeutic target for CVD? (ii) What is the evidence for intra-hepatocellular or cell-
autonomous functions of ANGPTL3, and what are the implications of such functions? 
 
2. Why is ANGPTL3 a promising cardiovascular therapy target? 
Due to its role as a crucial physiologic regulator of LPL and EL activity, ANGPTL3 has a 
major impact on the circulating lipoproteins, the loss of its function resulting in marked 
reductions of all major lipoprotein classes. Moreover, evidence from pre-clinical studies 
suggests that inactivation of ANGPTL3 reduces VLDL-TG secretion [19,23,30,31] and 
enhances the hepatic uptake of apoB100-containing lipoproteins [32] as well as VLDL-TG 
uptake into oxidative tissues [33]. The role of ANGPTL3 in human lipid metabolism was 
revealed in 2010 through the identification of individuals carrying LOF mutations in 
ANGPTL3 [14]. Genetic deficiency of ANGPTL3 was found to cause familial combined 
hypolipidemia (FHBL2, OMIM #605019) characterized by very low plasma TG, LDL-C and 
HDL-C concentrations. A number of LOF mutations have been characterized in the gene 
[14,34-36]. Of these, ANGPTL3 S17X is particularly interesting since it completely eliminates 
the protein and has been detected in three generations in the town of Campodimele in Italy 
[36,37]. The life expectancy of both females and males in this small town is exceptionally 
high, approximately 95 y. The inbred inheritance of ANGPTL3 LOF mutations is considered 
one of the factors underlying this remarkable longevity.  
A crucial question has arisen whether genetic abrogation of ANGPTL3 
associated with reduced circulating lipoprotein concentrations is protective against CVD. An 
extensive meta-analysis (a total of 21,980 CVD patients and 158,200 controls) 
demonstrated that carriers of ANGPTL3 LOF mutations have 34% lower odds of CVD  than 
control subjects [20]. Individuals belonging to the lowest tertile of circulating ANGPTL3 
concentration presented with a 29% lower myocardial infarction (MI) risk than the highest 
tertile. A reduction of CVD risk among ANGPTL3 LOF mutation carriers was replicated by 
Dewey et al. [21], who sequenced ANGPTL3 exons in 58,335 participants of the DiscovEHR 
genetics study. Here, subjects heterozygous for ANGPTL3 LOF variants displayed 
significantly lower serum TG (–27%), HDL-C (–4%) and LDL-C (–9%) concentrations than 
participants lacking the variants. Moreover, analysis of ANGPTL3 LOF variants in 13,102 




were found in 0.33% of the cases and in 0.45% of the controls (adjusted odds ratio, 0.59; 
95% CI, 0.41 to 0.85; p=0.004). These intriguing observations were further confirmed by 
follow-up studies employing four large population cohorts. An inverse-variance-weighted 
fixed-effects meta-analysis combining the DiscovEHR and the other population studies 
suggested an odds ratio of 0.61 (95% CI, 0.45 to 0.81; p<0.001) [21]. Interestingly, Lotta et 
al. [38] reported in a large human material (392,220 participants) that ANGPTL3 LOF 
variants were associated with greater protection against coronary disease than other LDL-
C-lowering genetic mechanisms (ANGPTL3 loss-of-function variants: odds ratio, 0.66; 95% 
CI, 0.52-0.83; 58 other LDL-C-lowering variants: odds ratio, 0.90; 95% CI, 0.89-0.91; P for 
heterogeneity = 0.009). 
The above epidemiological studies suggested that the plasma lipid/lipoprotein 
lowering observed in ANGPTL3 LOF carriers (the strongest effect being detected on TG 
levels) may precipitate as a drop of cardiovascular risk. The anticipated adverse effects of 
HDL lowering were apparently overridden by the beneficial reduction of TG and LDL-C. 
Reduction or inactivation of ANGPTL3 was, based on the above observations, considered 
a promising candidate CVD therapeutic strategy, and is being actively pursued.  
 What have we learned from the clinical trials on ANGPTL3 targeting? Trials on 
the suppression or inhibition of ANGPTL3 are ongoing at phases 2 and 3. The therapeutic 
agents under study are antisense oligonucleotides (AKCEA/IONIS-ANGPTL3-LRx, a 
GalNac-conjugated ASO, presently called Vupanorsen), which suppress the hepatic 
expression of ANGPTL3, or a human monoclonal antibody that inactivates circulating but 
not intra-hepatic ANGPTL3 (Evinacumab, Regeneron Pharmaceuticals). Moreover, in vivo 
genome editing by CRISPR-Cas9 technology is being developed as a tool to introduce LOF 
mutations in ANGPTL3. This novel approach has yielded the first promising results in a 
mouse model [39]. Results from both the ASO and the antibody trials have revealed 
significant decreases of plasma ANGPTL3 levels coinciding with reductions of all major 
lipoprotein classes. Graham et al. [23] showed in a phase 1 clinical trial that, after 6 weeks 
of ASO treatment on healthy adults, subjects receiving single or multiple doses of the ASO 
displayed 46.6 to 84.5% reductions of plasma ANGPTL3 protein (P<0.01 for all doses vs. 
placebo) and marked drops in the levels of TG (reductions of 33.2 to 63.1%), LDL-C (1.3 to 
32.9%), VLDL-C (27.9 to 60.0%), non-HDL-C (10.0 to 36.6%), apoB-100 (3.4 to 25.7%), and 




adverse side effect of certain ASO therapies [40,41], this or other serious treatment-
emergent adverse events (TEAE) or discontinuation of the therapy were not documented 
during the trial.  
After successful lipid lowering in mice and cynomolgus monkeys [19,21], the 
monoclonal antibody Evinacumab was administered in 83 healthy human volunteers with 
mildly to moderately elevated TG (150-450 mg/dl) or LDL-C (100 mg/dl) by Dewey et al. 
[21]. This resulted in a dose-dependent reduction in fasting TG of up to 76% and LDL-C of 
up to 23%. Similar observations were recently reported from a clinical trial on 
hypertriglyceridemic subjects by Ahmad et al. [24], who also measured significant reductions 
of VLDL-C in the Evinacumab-treated groups, in the absence of serious TEAE or 
discontinuation of the therapy.  
When one considers subjects with familial hypercholesterolemia (FH), for whom the efficacy 
of statin and PCSK9 inhibitor therapies is often not sufficient to reach their target lipid levels, 
ANGPTL3 targeting might give additional benefit. Consistent with this idea, Evinacumab 
administered for 4 weeks on top of intense lipid-lowering therapy resulted in a further 
reduction of TG (by 47%), LDL-C (by 50%), and HDL-C (by 36%) in a group of 9 
homozygous FH patients [22]. A more extensive phase 3 trial (ELIPSE HoFH; NCT03399786) 
on homozygous FH patients is ongoing with promising 1st endpoint results (49% reduction 
of LDL-C; significant drop of TG, TC, non-HDL-C and apoB). The idea of combining 
Evinacumab with other lipid-lowering therapies to reach maximal efficiency was recently 
tested in a pre-clinical setting by Pouwer et al. [42]. The authors studied the effect of ‘triple 
therapy’ consisting of evinacumab, the PCSK9 inhibitor alirocumab, and atorvastatin, on 
atherosclerosis in APOE*3-Leiden.CETP mice, a well-established model mimicking human 
hyperlipidemia. After 13-week western-type diet the mice received the pharmaceuticals for 
25 weeks, the ‘triple therapy’ yielding clearly better results than atorvastatin alone or 
atorvastatin + alirocumab (‘double treatment’). Atorvastatin alone reduced lesion 
progression by 28%, the double treatment completely blocked lesion progression and 
diminished lesion severity, increasing their collagen content, while the triple therapy 
regressed the lesions in thoracic aorta by 50% and in the aortic root by 36%, increasing their 
collagen and reducing their macrophage content. All the above pre-clinical and clinical trials 
strongly suggest that residual risk remaining after statin-PCSK9 inhibitor treatment can be 




antibody therapies elicited apoB reductions ranging from -14% to -46%. Considering a 
recent report suggesting that the clinical benefit of TG and LDL-C lowering may in fact be 
proportional to the absolute change in apoB  [43], this may be a crucial effect of ANGPTL3-
targeting therapy. The above studies and the evidence in favor of employing ANGPTL3 as 
cardiometabolic therapy target are summarized in Table 1. 
Table 1. Evidence for lipid lowering and cardioprotection upon loss or suppression of ANGPTL3 
activity/expression. 
Method Species Documented effect Reference(s) 
Genetic loss-of-
function (LOF) 
Human Reduction of TG, LDL-C, HDL-
C 
 [14] 
 Human Reduction of TG, TC, LDL-C, 
HDL-C, ApoB, ApoA-I 
 [15,44]  
 Human LOF carriers, OR1 of CAD 0.66; 
Lowest tertile of ANGPTL3 
conc. OR 0.65 relat. to highest 
tertile;  Reduction of TG, TC, 
LDL-C HDL-C  
 [20] 
 Human LOF carriers, OR of CAD 0.59; 
Reduction of TG, TC2, LDL-C, 
HDL-C  
[21]  
 Human LOF carriers, OR of CHD 0.66; 
Other LDL-C lowering variants, 
0R 0.90 
[38] 
 Human Reduction of TG, TC, LDL-C, 
HDL-C, ApoB, ApoA-I, FFA; 
Increase of IS3 
[16] 
 Mouse, Angptl3-/-  Reduction of TG, TC; Increase 




Human Reduction of TG (max −76%)5, 
LDL-C (−23%), HDL-C (−18%) 
[21] NCT01749878 
 
 Human (FH6) Reduction of LDL-C (mean 
−49%), apoB (−46%), non-HDL-
C (−49%), TG (−47%), HDL-C 
(−36%) 
[22] NCT02265952 
 Human (FH) Reduction of LDL-C (−49%), 
TG, TC, non-HDL-C and apoB 
NCT03399786 
 Human (hyper-TG) Reduction of TG (max −88%), 
TC (−34%), LDL-C (−25%), 
non-HDL-C (−40%), VLDL-C 
(−91%), apoB (−31%), HDL-C 
(−28%) 
[24] NCT01749878 
       NCT02107872 





Lesion area reduction 39% 
Necrotic area reduction 45% 
Reduction of TG, TC. VLDL-C 
[21] 
 Mouse, WT, Apoe-/-, 
Ldlr-/-, Lrp1-/-, Sdc1-/- 
Reduction of TG, TC, LDL-C, 
VLDL-C 
[31] 
 Mouse, WT, 
dyslipidemic 






1Odds ratio; 2Total cholesterol; 3Insulin sensitivity; 4White adipose tissue, 5For human clinical 
studies a maximum or mean (for ref. [22]) % reduction of plasma lipids or lipoproteins are given. 
The numbers are not directly comparable since they have been picked from different single or 
multiple dose regimes in the different studies. 6Familial hypercholesterolemia; 7Cholesterol ester 
transfer protein 
 
To conclude, ANGPTL3 is currently considered a highly promising 
cardiovascular therapy target. Its inactivation alone or especially in combination with other 
lipid-lowering therapies holds great promise particularly for subjects with hard-to-treat 
dyslipidemias inflicting a high CVD risk. Moreover, additional benefit concerning metabolic 
disease is suggested by the observations demonstrating that ANGPTL3 deficiency is 
associated with increased insulin sensitivity in both human subjects [16] and mice [33]. Even 
though the Evinacumab antibody therapy has shown positive results, the ASO therapy and 
the emerging CRISPR-Cas9 approach are likely to gain ground in the future.  However, both 
of these induce long-term or permanent suppression of the hepatic ANGPTL3 expression, 
thus also afflicting the putative intra-hepatocellular or cell-autonomous functions of 
ANGPTL3 – detailed study of these functions is therefore a necessity. 
 
3. ANGPTL3 and non-alcoholic fatty liver disease (NAFLD) 
3.1 Familial hypobetalipoproteinemias and fatty liver 
As indicated above, LOF mutations in the ANGPTL3 gene cause familial combined 
hypolipidemia 2 (FHBL2, OMIM #605019) associated with significantly reduced plasma 
levels of all apoB-100 containing lipoproteins as well as HDL. Also several variants of the 
 Mouse, 
APOE*3Leiden.CETP 
Evinacumab + alirocumab + 
atorvastatin, lesion regression; 
Reduction of TC, non-HDL-C, 
VLDL-C, LDL-C 
[42] 
ASO Human Reduction of TG (max −63%), 
LDL-C (−33%), VLDL-C 
(−60%), non-HDL-C (−37%), 
ApoB (−26%), ApoC-III (−59%), 
ApoA-I, Lp(a) 
[23] NCT02709850 
 Mouse, Ldlr-/- Lesion area reduction 52% 
Reduction of TG, LDL-C 
[23] 
siRNA Mouse, WT, ob/ob 
hCETP/ApoB-100 
Apobec-/- hApoB Tg 
Ldlr-/- 
Reduction of TG, HDL-C, LDL-
C 
Reduction of of TG, LDL-C 








APOB gene are connected to low plasma apoB-100 and LDL-C concentrations, causing 
familial hypobetalipoproteinemia 1 (FHBL1, OMIM #615558). In FHBL1 apoB-100 plasma 
levels are generally <5th percentile whereas LDL-C concentrations are in the range of 200-
500 mg/L  [45,46]. Of note, FHBL1 subjects are prone to develop NAFLD  [47-49]. Using 
stable isotope techniques it was demonstrated that heterozygous FHBL1 subjects have a 
significantly reduced hepatic apoB-100 secretion rate, attenuated production of LDL-
associated apoB-100, and highly enhanced catabolism of VLDL particles  [50,51].  
Although an elevated prevalence of liver steatosis in FHBL1 has been firmly 
documented, the hepatic neutral lipid levels in FHBL2 are as yet not well established. There 
are only a few investigations addressing the hepatic lipid status in ANGPTL3 deficient 
subjects. Musunuru et al. [14] characterized one ANGPTL3 LOF mutation kindred, and signs 
of fatty liver were not detected, suggesting that ultrasonography could be employed to 
discriminate ANGPTL3 (FHBL2) from APOB deficiency (FHBL1), but not from 
hypobetalipoproteinemia due to PCSK9 mutations, where advanced fatty liver is usually not 
observed. Minicocci et al.  [44] studied 115 FHBL2 individuals with 13 different ANGPTL3 
variants (14 homozygotes, 8 compound heterozygotes, and 93 heterozygotes) and about 
400 control subjects. Detailed examination for the presence of hepatic steatosis was 
performed among 64 ANGPTL3 S17X variant carriers and 103 control subjects. The authors 
did not observe increased prevalence of liver steatosis in this FHBL2 group compared with 
the non-carrier controls. Furthermore, there was no association between the severity of 
steatosis and the FHBL2 status. Di Costanzo et al.  [52] carried out a direct comparison of 
the hepatic lipid phenotypes of FHBL1 and FHBL2. Altogether 350 subjects, 67 
heterozygous carriers of APOB mutations (FHBL1 subjects), 57 heterozygote and 6 
homozygote ANGPTL3 variant carriers (FHBL2 subjects), and 220 normolipidemic controls 
were included. Prevalence and degree of hepatic steatosis were analyzed by 
ultrasonography. The major outcome of this study was that, when comparing to the controls, 
the prevalence and severity of hepatic steatosis were significantly increased in heterozygous 
FHBL1 subjects (P<0.001), while the FHBL2 participants did not differ from controls. The 
hepatic consequences of FHBL2 thus seem to be strikingly different from those of APOB-
linked FHBL1 in which elevated prevalence of hepatic steatosis has been consistently 
demonstrated. 




Experimental studies have suggested a potential role of the angiopoietin-like proteins, 
especially ANGPTL3, in the pathogenesis of metabolic syndrome, hepatic steatosis, and 
more advanced forms of liver disease. One study focused on measuring ANGPTL3 plasma 
levels in patients with definite nonalcoholic steatohepatitis (NASH, n=40), borderline NASH 
(n=8), simple fatty liver (n=9), and healthy control subjects without liver disease (n=14). The 
results suggested that plasma ANGPTL3 levels are increased in the more severe cases of 
NAFLD in association with insulin resistance  [53]. Another single center, cross-sectional 
study among approximately 1000 Japanese undergoing routine health checks also 
observed elevated circulating ANGPTL3 concentrations in subjects with impaired liver 
function and hepatic inflammation  [54]. The DiOGenes (Diet, Obesity and Genes) study 
examined the role of ANGPTL3 in lipoprotein metabolism and liver health status  [55]. The 
authors measured ANGPTL3 levels in relation to body mass index, plasma lipid profile, and 
markers of hepatic steatosis before and during weight loss. Moreover, genetic variants 
affecting plasma ANGPTL3 levels were defined through protein quantitative trait locus 
(pQTL) analysis. The major findings were a strong negative correlation between plasma 
ANGPTL3 concentration and ASAT activity, and a positive association with cytokeratin 18 
(CK-18), independent of weight loss. CK-18 is a major hepatic intermediate filament protein, 
and plasma CK-18 acts as a biomarker for the apoptotic death of hepatocytes, NASH and 
hepatic inflammation  [56]. The authors of the DiOGenes study suggested that elevation in 
plasma ANGPTL3 concentration results from hepatic inflammation, or that ANGPTL3 itself 
could play a role in the development of liver malfunction. In vitro support for these 
suggestions is provided in the study by Szalowska et al.  [57], where inflammation was 
induced in vitro in human liver tissue, and ANGPTL3 appeared as a biomarker associated 
with the inflamed status. Of note, no increase of liver fat content was reported in mice treated 
with ANGPTL3 ASO, and no significant change in biomarkers of liver function was observed 
in human subjects who received the ASO  [23], in contrast to the hepatotoxicity frequently 
observed upon treatments with inhibitors targeting the microsomal triglyceride transfer 
protein (Lomitapide; [58]) or apoB-100 (Mipomersen;  [59]).    
Interestingly, Ruhanen et al.  [60] recently demonstrated that in human 
hepatocytes subjected to ANGPTL3 knock-down (KD) several lipid classes were enriched 
in n-6 and n-3 polyunsaturated fatty acids (PUFA), and this phenomenon coincided with an 
elevation of a number of PUFA-derived lipid mediators relevant for the resolution of 




7). However, because of the controversy on the applicability of non-invasive biomarkers as 
metrics of liver derangements, future investigations should analyze liver biopsies to more 
reliably evaluate the role of ANGPTL3 in liver disease. 
 
4.  Modulation of hepatic lipoprotein uptake by ANGPTL3 
The reduction of circulating lipoproteins upon ANGPTL3 LOF can be partially explained by 
the increase in LPL and EL activity caused by the loss of secreted ANGPTL3. However, the 
loss of ANGPTL3 also may contribute to this by enhancing hepatic lipoprotein uptake. The 
decrease in LDL-C upon ANGPTL3 KD in vivo in mouse appeared to be mediated via the 
LDL receptor (LDLR), as suggested by experiments employing Ldlr-deficient 
Apobec1−/−/ApoB-100 transgenic mice [32]. However, contradicting in vivo results were 
reported by Graham et al. [23] who found a similar drop of LDL-C upon ANGPTL3 ASO-
treatment in both wild-type and Ldlr-/- mice, implying that the drop of LDL in this case may 
not depend on functional LDLR. While the best characterized high affinity receptor for LDL 
is LDLR, a recent LDL transcytosis study by Armstrong et al. [61] showed that LDL co-
localized partially with the scavenger receptor SR-BI and overexpression of SR-BI increased 
LDL transcytosis, whereas SR-BI knockdown by siRNA significantly inhibited this process. 
This suggests that hepatic SR-BI could facilitate LDL uptake in Ldlr-/- mice and thus 
contribute to the reduced plasma LDL-C levels upon suppression of ANGPTL3, an issue 
that warrants further study.  
Interestingly, deficiency of ANGPTL3 in the HuH7 and HepG2 hepatocellular carcinoma 
cells in vitro was shown to result in an elevated rate of LDL and VLDL uptake. Further, the 
ANGPTL3 depletion induced intracellular accumulation of long-chain TG and apoB-100, as 
well as elevated expression of both LDLR and LDLR-related protein 1 (LRP1) [32] (Fig. 2). 
Since ANGPTL3 function through inhibition of LPL is hardly relevant in experiments 
employing cultured hepatocytes, the above in vitro results suggest that ANGPTL3 modulates 
LDL uptake through an intracellular, or cell-autonomous mode of action. The study of Wang 
et al. [31] employing antibody inhibition of ANGPTL3 in mouse did not observe LDLR-
dependency of the drop of circulating LDL, and this is no doubt the case also in homozygous 
human FH patients carrying LDLR null mutations but still exhibiting a marked drop of LDL-
C upon Evinacumab therapy [22]. These observations suggest that inhibition of the 




VLDL secretion through reduction of FA flux towards the liver, results in a marked drop of 
circulating LDL independent of the LDLR pathway (Fig. 2; see below).  
 
5.  ANGPTL3 regulates hepatocyte VLDL secretion.  
Plasma VLDL and LDL levels are very low in ANGPTL3 deficient humans and mice. To what 
extent can this be attributed to inhibition of VLDL secretion by hepatocytes? Targeting 
ANGPTL3 with a monoclonal antibody (Evinacumab, REGN1500) in a number of genetically 
modified mouse models reduced the plasma total levels of TG and cholesterol, including 
those in the VLDL fraction, and the hepatic TG secretion, without effect on plasma apoB 
concentration or VLDL/LDL particle numbers [19,21,31]. The study of Wang et al. [31] 
suggested a selective effect of ANGPTL3 inhibition on hepatic TG but not apoB secretion. 
Such an effect could be explained by enhanced LPL activity in oxidative tissues and possibly 
reduced adipose tissue lipolysis  [62], resulting in a reduced flux of FA to the liver and, as a 
consequence, reduced assembly and secretion of large VLDL particles (Fig. 2). A somewhat 
contradicting observation was made by Xu et al. [32], who reported reduced apoB-100 
accumulation in the growth medium of HuH7 and HepG2 cells subjected to ANGPTL3 KD. 
This finding may also suggest that the consequences of in vivo inhibition of circulating 
ANGPTL3 may include cross-talk between liver and tissues such as WAT, a connection that 
is lacking when studying hepatocytes in culture. According to Wang et al. [31], the turnover 
of LDL or VLDL was not affected in mice treated with ANGPTL3-inhibiting antibody, 
consistent with the notion that the observed -lipoprotein reduction was largely due to 
inhibition of VLDL secretion.  
ASO-mediated silencing of Angptl3 in human subjects and mouse liver affects, 
in addition to circulating ANGPTL3, the intra-hepatocellular protein. In both humans and 
mice, similar results of ASO treatment were reported: In humans, the treatment resulted in 
a significant reduction of TG, LDL-C, VLDL-C, non-HDL-C, apoB-100 and ApoC-III [23]. In 
the siRNA-mediated Angptl3 knock-down study of Xu et al. [32], lipid phenotypes resembling 
the above were observed in both wild-type and obese mice, while in more ‘human-like’ 
hCETP/ApoB-100 double transgenic animals, no drop of HDL-C was evident. Further, 
silencing of ANGPTL3 in HuH7 and HepG2 hepatocellular carcinoma cell lines caused a 




immortalized human hepatocytes (IHH) induced a shift from the secretion of large VLDL1-
like particles to more lipid-poor VLDL2-like particles upon insulin stimulation [30]. Taken 
together, these observations suggest that intracellular ANGPTL3 acts as a regulator of VLDL 
secretion. However, the underlying mechanism(s) remain poorly understood. In a recent 
report, Ruhanen et al.  [60] showed that the cholesterol ester (CE) levels are reduced in 
ANGPTL3 depleted hepatocytes, apparently mediated by downregulation of acyl-
CoA:cholesterol acyltransferase1 (SOAT1) expression. Burnett et al.  [63] have previously 
demonstrated a role of SOAT1 in VLDL secretion from hepatocytes, and the cellular CE 
levels are reported to affect apoB-100 and VLDL secretion  [64,65]. The defects observed 
in VLDL secretion upon ANGPTL3 depletion may thus, in part, depend on the availability of 
intra-hepatocellular CE.  
Another clue to the mechanisms that could putatively explain the impact of 
ANGPTL3 on VLDL secretion is provided by the study of Ruhanen et al.  [60], who showed 
that ANGPTL3 knock-down hepatocytes are enriched with polyunsaturated fatty acid 
(PUFA)-containing lipid species (see paragraph 7). The changes in the FA composition may 
affect the assembly, composition and secretion of VLDL particles and also their further 
hydrolysis properties by LPL. Importantly, n-3 and n-6 PUFA intake in humans has been 
shown to reduce plasma VLDL, mainly by enhancing VLDL lipolysis and uptake  [66]. On 
the other hand, lysophosphatidylcholine acyltransferase 3 (LPCAT3) deficient hepatocytes 
depleted of arachidonic acid (20:4n-6) containing phospholipid species were unable to 
secrete mature VLDL particles, apparently due to defects in forming the membrane 
curvature required for VLDL assembly  [67]. This illustrates well how a change in the FA 
composition of lipids can modulate VLDL secretion. More studies, however, are required to 
determine whether the PUFA enrichment in ANGPTL3-depleted hepatocytes indeed affects 
the secretion of VLDL. We are tempted to speculate that the accumulation of PUFAs might 
favor the production of small VLDL particles or ones acting as a better substrate for LPL and 
hepatocellular uptake.  
6. Connection of ANGPTL8 and ANGPTL3 function in the liver 
Human ANGPTL8, a functional partner of ANGPTL3, is predominantly expressed in the liver, 
while mouse Angptl8 is expressed in both the liver and the adipose tissues. Studies on 
ANGPTL8 have provided evidence for intracellular functions in the regulation of metabolism 




HepG2 cells via the Akt-GSK3β or Akt-FOXO1 pathway  [68]. Moreover, ANGPTL8 
oligomers were demonstrated dampen NF-B activation through selective autophagic 
degradation of IKK in HepG2 cells, with consistent in vivo observations made in LPS-
treated mice [69]. Importantly, ANGPTL3 relies on ANGPTL8 in the regulation of LPL-
mediated TG hydrolysis: ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit LPL  
[70]. On the other hand, ANGPTL8 itself has a functional LPL-inhibitory motif, but inhibits 
LPL and increases plasma TG levels only in the presence of ANGPTL3  [71]. ANGPTL8 can 
form complexes with ANGPTL3 with varying stoichiometric ratios, the assembly of these 
complexes taking place intra-hepatocellularly. In this process ANGPTL8 binds to the N-
terminal domain of ANGPTL3 and mediates proteolytic cleavage of ANGPTL3 via exposure 
of its cleavage site or recruitment of relevant hepatic proteases  [7,72] (Fig. 3). Thus far 
there are no data available on a putative role of ANGPTL8 in hepatic lipid metabolism under 
conditions in which the liver is devoid of ANGPTL3 biosynthesis, i.e. FHBL2. 
7. Impacts of ANGPTL3 on the fatty acid (FA) composition of hepatocyte lipids and 
on PUFA-derived lipid mediators 
To date, only a handful of studies have addressed the putative effects of ANGPTL3 on 
intrahepatic lipid metabolism and in even fewer studies detailed information on intrahepatic 
lipid molecular species composition or FA profile has been reported. The limited information 
on how ANGPTL3 affects hepatic FA has been gained from animal or in vitro studies. In a 
study conducted using mice kept on a high-fat high-cholesterol diet, neutralizing ANGPTL3 
in the circulation with a multiple dose treatment of the antibody Evinacumab (REGN1500) 
did not change the hepatic expression of genes related to de novo lipogenesis or FA 
oxidation, and, consistently, there was no change in liver fat content [19]. Similarly, there 
were no changes in the transcription of genes involved in fatty acid synthesis, desaturation, 
or β-oxidation in the livers of Angplt3-/- mice [33]. In these knock-out mice on a chow diet, 
the hepatic level of FA 18:2n-6 (linoleic acid) or 16:1n-7 (palmitoleic acid) did not change 
nor did the ratio of the exogenous FAs 18:2n-6 or 18:3n-3 (α-linolenic acid) to 16:1n-7.  
In cultured human hepatocytes subjected to ANGPTL3 knock-down (KD), 
however, changes in lipid metabolism and in the FA composition of lipids have been 
observed. Both transcriptomics and lipidomics were employed to study the effects of 
ANGPTL3 KD in IHH  [60]. ANGPTL3 depletion led to statistically significant changes in 




metabolism’, ‘Biosynthesis of unsaturated fatty acids’, ‘Fatty acid elongation’, ‘Fatty acid 
degradation’, ‘Fatty acid biosynthesis’, and ‘Arachidonic acid metabolism’. These 
observations were accompanied by significant alterations in the total FA profile of the cells, 
showing a reduction of monounsaturated FA (MUFA) and an increase in both n-6 and n-3 
PUFA. The relative MUFA depletion and PUFA increase were reflected in the lipid species 
profiles of major membrane phospholipids, the total levels of which, however, were not 
affected by the ANGPTL3 KD. In addition, there were similar FA changes observed in the 
species profile of CE, and the total CE level was reduced upon ANGPTL3 depletion. 
Interestingly, Xu et al. [32] found that in ANGPTL3 KO human hepatocellular carcinoma 
cells, depletion of ANGPTL3 resulted in intracellular TG and cholesterol accumulation as 
well as an increase of long-chain TG, TG 58:8 being the single most affected TG species. 
Inversely, short-chain TG and diacylglycerols decreased in the ANGPTL3 depleted cells.  
Both n-3 and n-6 PUFA are precursors of bioactive lipid mediators, important 
signaling molecules orchestrating inflammation and its resolution. The imbalance of pro-
resolving and pro-inflammatory lipid mediators plays a role in the development of 
atherosclerotic CVD  [73-77]. ANGPTL3 KD resulted in our IHH model in an enhanced 
production of lipid mediators  [60], likely as a consequence of both increased substrate 
PUFA availability and upregulation of mRNA expression of cytosolic phospholipase A2, 
which releases PUFA from membrane phospholipids  [78,79]. Most of the mediators 
elevated in the ANGPTL3 KD hepatocytes have known functions in promoting the resolution 
of inflammation, recovery from cardiovascular events, protection from ER stress, or 
attenuation of insulin resistance and hepatic fat accumulation  [80-85]. However, since also 
the production of several 20:4n-6 derived pro-inflammatory lipid mediators was enhanced in 
the ANGPTL3 KD cells, one should interpret the results with caution. Concerning the main 
topic of this review, the changes observed in the FA composition of hepatocellular lipids as 
well as the alterations of PUFA-derived lipid mediators are no doubt due to cell-autonomous 
effects of ANGPTL3 KD. They can be mediated through altered expression or activity of 
lipid-modifying enzymatic machineries, and possibly the apparatus responsible for the 
uptake and metabolism of lipids, FA and glucose from the growth medium. 
 
8. What does the plasma metabolome of ANGPTL3-deficient human subjects tell 




Human plasma metabolome analysis revealed that ANGPTL3 LOF variant carriers have 
significantly higher concentrations of 3β-hydroxybutyrate (a ketone body) compared to 
normal human subjects, which may reflect enhanced hepatic -oxidation of FA in the LOF 
variant carriers  [86]. This could obviously result in reduced TG synthesis and packaging 
into newly synthesized VLDL particles, and thus be one of the mechanisms contributing to 
the low plasma apoB-100 lipoprotein levels in ANGPTL3-deficient or -depleted subjects. Of 
note, Wang et al. [31] found no evidence for enhanced hepatic FA oxidation in mice treated 
with Angptl3-inactivating antibody, consistent with the view that intra-hepatocellular KD of 
the gene may be required for such an effect. Similar to β-hydroxybutyrate, lactate was 
consistently higher at fasting and after a meal challenge in human subjects with complete 
ANGPTL3 deficiency  [86]. This may indicate an enhanced conversion of pyruvate to lactate 
instead of its routing to the acetate pathway, consistent with the reduced concentration of 
acetate observed in the LOF carriers. These observations suggest that ANGPTL3 deficiency 
causes a modest but significant shift in the hepatic energy substrate utilization. 
 
9.  ANGPTL3 and insulin sensitivity 
ANGPTL3 LOF carriers exhibit enhanced insulin sensitivity and low plasma free FA levels 
[16]. The decrease in free FAs observed in these subjects could be the result of reduced 
adipocyte lipolysis in the absence of ANGPTL3  [62]. Moreover, there is evidence for a 
regulatory link between insulin and ANGPTL3: Plasma ANGPTL3 was reduced upon insulin 
infusion in human subjects, and insulin treatment suppressed the expression and secretion 
of ANGPTL3 by IHH [6]. A recent study utilizing non-human primates shows that the plasma 
concentration of ANGPTL3 was elevated in fructose induced insulin resistance and 
correlated positively with HOMA-IR, an index of insulin resistance  [87]. In an elegant study 
on Angptl3-/- mice, Wang et al. [33] demonstrated an increase of insulin sensitivity, and 
reduced FA but clearly elevated glucose uptake into WAT in the fed state. This alteration in 
WAT substrate utilization could provide an explanation for the improvement of insulin 
sensitivity observed in both humans and mice deficient in ANGPTL3. A consistent effect of 
Angplt3 inactivation on insulin sensitivity in mice treated with ASO was reported by Graham 
et al. [23]. Ruhanen et al.  [60] showed that PUFA-containing lipid species were enriched in 
ANGPTL3 KD hepatocytes and that a similar PUFA enrichment was present in the TG of 




altered lipid composition of the lipoproteins in the ANGPTL3 deficient subjects remains an 
intriguing topic of future study. However, it might affect the quality of FAs stored in 
adipocytes but also in tissues involved in ectopic lipid storage, promoting insulin sensitivity. 
To conclude, the mechanisms through which depletion of ANGPTL3 improves whole body 
insulin sensitivity are thus far not well understood. However, present evidence suggests that 
reduced FA uptake into WAT and lipolysis, as well as elevated glucose uptake into WAT 
may play roles here. Further, the enrichment of circulating lipoproteins with PUFA in subjects 
with low ANGPTL3 activity could favorably modify the fatty acid composition of tissues 
crucial for insulin sensitivity. Moreover, ANGPTL3 KD was reported to reduce gluconeogenic 
gene expression and reduce the secretion of TG-rich VLDL by hepatocytes in culture  [30], 
with putative insulin sensitizing effects.  
10. Which physiological functions of ANGPTL3 can be considered cell autonomous? 
A number of in vitro findings made by employing cultured hepatocyte models suggest cell-
autonomous functions of ANGPTL3 in controlling hepatocellular VLDL secretion, β-
lipoprotein uptake [32], or the insulin regulation of VLDL assembly/secretion [30]. Since 
functional impact in cultured hepatocytes cannot be attributed to alterations of LPL activity 
and the resulting FA fluxes, the above in vitro observations almost certainly reflect cell-
autonomous functions of the protein. The same holds true for the changes observed in the 
FA composition of lipids, and the alterations in the transcriptome of cultured IHH subjected 
to ANGPTL3 KD  [60]. We are tempted to speculate that the alterations in gene expression 
observed in the hepatocytes depleted of ANGPTL3 could relate to the altered FA 
metabolism, considering that FAs and their derivatives regulate a number of key nuclear 
receptors or transcription factors, such as peroxisome proliferator activated receptors 
(PPAR), hepatic nuclear factors (HNF), retinoid X receptors (RXR), and sterol regulatory 
element binding protein 1c (SREBP-1c)  [88-91].  
In vivo observations are more difficult to interpret from the point-of-view of cell 
autonomy, due to the complexity of biological systems. Most of the effects of ANGPTL3 
antibody inhibition observed in mouse and man [19,21,22,24,31,42] can be attributed to the 
activation of LPL and resulting alterations in FA fluxes between lipoproteins and tissues, as 
well as the resulting indirect effects on hepatic lipoprotein production. However, the in vivo 
plus in vitro ANGPTL3 KD study of Xu et al. [32] contains truly interesting evidence for a role 




enhancement of hepatic LDL/VLDL uptake, and provides evidence suggesting that this is 
due to elevated expression of LDLR and LRP1 by ANGPTL3-depleted hepatocytes (Fig. 3). 
Of note, significant reduction of LDL-C is observed not only in human subjects treated with 
ANGPTL3 ASO  [23] but also upon Evinacumab treatment  [21,22,24]. This suggests that 
an intrahepatocellular LDLR/LRP1 induction cannot be the major mechanism underlying the 
LDL-C lowering effect. It rather implies that altered fatty acid fluxes modulating hepatic VLDL 
assembly/secretion and the turn-over properties of the resulting -lipoproteins must play a 
more important role. 
One may wonder by what mechanism ANGPTL3, which has an N-terminal 
signal sequence, is synthesized through the endoplasmic reticulum (ER) membrane into the 
ER lumen and is secreted by hepatocytes through the canonical secretory route, could 
execute intracellular or cell-autonomous functions. Obviously, it could participate in 
lipoprotein assembly within the secretory pathway luminal compartments, in the ER, the 
Golgi apparatus and within secretory vesicles (Fig. 3). This type of intracellular function has 
in fact been demonstrated for another crucial regulator of lipoprotein metabolism, the 
phospholipid transfer protein (PLTP), a secreted plasma factor that also plays a major role 
in the assembly of apoB-containing lipoproteins in hepatocytes  [92,93]. The intracellular 
function of PLTP most likely involves transfer of phospholipids to the nascent apoB 
lipoproteins within the secretory pathway. However, PLTP has also been found within the 
nucleus of neuronal cells, where it is suggested to execute as yet poorly understood 
functions  [94]. Similar to PLTP, ANGPTL3 could regulate VLDL assembly and secretion 
through an activity within the secretory pathway of hepatocytes, where it is activated by furin 
cleavage  [95]. Whether an isoform of ANGPTL3 could be found localized to the cytoplasmic 
or nuclear compartments is thus far not known. In the NCBI database there are no 
alternatively spliced variants of ANGPTL3 that would lack a signal sequence – however, this 
does not exclude their existence, or the signal sequence could under some circumstances 
be masked. Moreover, the protein secreted to the cell surface could be internalized through 
the endocytic pathway (Fig. 3) and execute activity within the endo-lysosomal 
compartments, recycle to the trans-Golgi, or possibly even exit the endomembrane system. 
These intriguing questions warrant detailed study in the future.  
An interesting finding published almost 20 years ago showed that ANGPTL3 is 




based assays with recombinant proteins and direct binding experiments that ANGPTL3 
bound to αVβ3-integrin and was thereby able to induce endothelial cell migration and 
adhesion. The Fibrinogen-like domain (FLD) of ANGPTL3 was sufficient for the integrin 
binding and induction of angiogenesis. The role of integrin αVβ3 as a receptor for ANGPTL3 
has been afterwards verified in other locations such as in kidney podocytes  [97,98]. 
Interestingly, ANGPTL3 was in podocytes shown to induce actin filament rearrangement, 
mediated by integrin αVβ3-dependent FAK and PI3K phosphorylation and Rac1 activation. 
Actin cytoskeleton could also be a target of ANGPTL3–integrin action in the liver. 
Furthermore, the PI3K–Akt pathway is a crucial part of the signaling that controls TG 
metabolism in hepatocytes. We therefore speculate that hepatic ANGPTL3 deficiency could 
suppress integrin αVβ3/PI3K/Akt signaling and thereby affect liver TG homeostasis. 
ANGPTL3 secreted by hepatocytes could engage αVβ3 on the surface of the same or near-
by cells, resulting in cell-autonomous regulation of TG metabolism and VLDL secretion (Fig. 
3). Moreover, ANGPTL3 may represent a local liver-specific angiogenic factor regulating 
vascular responses by binding to αVβ3-integrin expressed on the liver endothelium. 
To conclude, accumulating evidence suggests that manipulating the expression 
of hepatic ANGPTL3 does have cell-autonomous impacts on hepatocellular gene 
expression and lipid metabolism. The topic has thus far been addressed only in a handful of 
studies and definitely deserves more thorough investigation.     
 
 
11. Conclusions and future perspectives 
ANGPTL3 is a highly promising new cardiometabolic therapy target. Nucleic acid-based 
therapeutic approaches that dampen the hepatic expression of this protein not only affect 
its lipase inhibitor activity in circulation but also its putative, emerging intra-hepatocellular or 
hepatocyte cell-autonomous activities. The evidence thus far suggests that suppression of 
ANGPTL3 expression has quite significant effects on the hepatocyte transcriptome  [60], 
glucose uptake, insulin sensitivity [23,30], LDL/VLDL uptake [32], VLDL assembly/secretion 
[23,32], the PUFA content of hepatocyte lipids, and the concentrations of PUFA-derived lipid 
mediators  [60]. While most of these putatively cell-autonomous impacts of ANGPTL3 




ANGPTL3 suppression, it is important to realize that among them there may also be ones 
with potential to be harmful in long term. Therefore, detailed study of the intra-hepatocellular 
functions of ANGPTL3 is definitely warranted.    
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Fig. 1. The structure of ANGPTL3 and its functional partner ANGPTL8. Abbreviations: SS, 
signal sequence (translocation into the ER for secretion); SE1, LPL-specific epitope; CCD, 
coiled-coil domain; LR, linker region; FLD, fibrinogen-like domain; LPL, lipoprotein lipase. 
The SE1 epitope is required for binding LPL and inhibiting its activity. The coiled-coil 
domains mediate oligomerization of ANGPTL3 and -8 with each other and possibly with 
other partners. The FLD (absent in ANGPTL8) mediates binding of ANGPTL3 to its cellular 
receptor αVβ3-integrin, mediating signaling responses and the function of ANGPTL3 in 
angiogenesis. The image of ANGPTL3 FLD structure was reproduced from  [99] under a 
Creative Commons license http://creativecommons.org/licenses/by/4.0/.   
 
Fig. 2. The impacts of hepatic loss of ANGPTL3 expression or its antibody-mediated 
inhibition in circulation, on metabolic fluxes in white adipose tissue (WAT), striated muscle 
and liver. The image collates data from studies of human subjects with loss-of-function 
variants, Angptl3-/- knock-out mice, pharmacologic inhibition studies in human or mice, and 
work carried out on cultured hepatocyte models. (A) Suppression of hepatocyte ANGPTL3 
expression reduces the post-prandial routing of fatty acids (FA) from triglyceride-rich 
lipoproteins (TRL) for storage in WAT, while increasing glucose (Glc) uptake into WAT and 
adipose de novo lipogenesis (DNL). Meanwhile it increases the hepatocyte uptake of Glc, 
LDL, and TRL remnants (TRL remn.), and inhibits the secretion of VLDL by the liver. (B) 
Inhibition of circulating ANGPTL3 with a humanized antibody (Ab) enhances the activity of 
LPL on TRL at oxidative tissues such as muscle, esulting in elevated FA uptake into these 
tissues and reduced FA flux to the liver. The reduced FA availability in the liver in turn 
reduces the hepatic secretion of VLDL triglycerides. Of note, the loss or knock-down of 
ANGPTL3 in hepatocytes also results in the same metabolic effects as its inhibition in the 
circulation; The physiologic consequences of depleting ANGPTL3 expression thus 





Fig. 3. The biosynthesis and putative cell autonomous functions of ANGPTL3 within 
hepatocytes. Points where ANGPTL3 can potentially execute cell autonomous functions are 
indicated with numerals (1-4). In the nucleus ANGPTL3 expression is regulated positively 
by liver X receptors (LXR) and hepatic nuclear factor 1α (HNF1α), and negatively by insulin, 
leptin, and thyroid hormone receptor β (TRβ). After synthesis and translocation into the 
endoplasmic reticulum, ANGPTL3 can form a complex with the related ANGPTL8, and the 
proteins are transported through the secretory pathway; Part of ANGPTL3 is on the way 
cleaved by the protease furin or other kexin-type proteases, which increases its biological 
activity. (1) Within the secretory pathway lumen ANGPTL3 may potentially regulate the 
assembly/lipidation/secretion of nascent VLDL particles. (2) After reaching the cell surface 
ANGPTL3 can via its fibrinogen-like domain bind to αVβ3-integrin or other as yet unknown 
receptors to induce signaling responses within the cell. These include the PI3K/Akt/mTOR 
pathway, which plays an important role in controlling VLDL assembly and secretion. 
Moreover, this pathway regulates glucose (Glc) uptake and metabolism. (3) ANGPTL3 
bound to cell surface receptors could also be internalized via endocytosis, and execute 
intracellular functions within endosomes, or be routed from these organelles to the Golgi 
complex. (4) Depletion of ANGPTL3 in hepatocytes is reported to enhance the expression 
of LDL-receptor (LDLR) and LDLR-related protein 1 (LRP1), and to increase the 
hepatocellular uptake of LDL and TRL remnants (TRL remn). In addition to these four 
putative mechanisms, ANGPTL3 depletion is reported to increase the polyunsaturated fatty 
acid (PUFA) content of hepatocyte lipids, the synthesis of PUFA-derived lipid mediators, 
and possibly to stimulate the β-oxidation of fatty acids –– processes which could reflect cell 
autonomous functions of the protein.  
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